Press Releases Annexon, Inc.

Equities

ANNX

US03589W1027

Real-time Estimate Cboe BZX Other stock markets 01:11:11 30/04/2024 am IST			5-day change	1st Jan Change
4.72 ^USD	+0.43%		+2.42%	+2.53%

01/04	JPMorgan Raises Price Target on Annexon to $13 From $11, Maintains Overweight Rating	MT
27/03	Wells Fargo Adjusts Price Target on Annexon to $12 From $11, Maintains Overweight Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ANNEXON REPORTS INDUCEMENT GRANTS TO NEW EMPLOYEES UNDER NASDAQ LISTING RULE 5635(4)	17/04	AQ
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)	17/04	GL
Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference	03/04	GL
Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference	03/04	AQ
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones	27/03	GL
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)	19/03	GL
Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference	27/02	GL
Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference	27/02	AQ
ANNEXON REPORTS INDUCEMENT GRANT TO NEW EMPLOYEE UNDER NASDAQ LISTING RULE 5635(4)	21/02	AQ
Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic Approach	21/02	GL
Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic Approach	21/02	AQ
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)	21/02	GL
Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases	08/01	GL
Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference	27/12	GL
Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference	27/12	AQ
Annexon : ANX1502 First in Human SAD / MAD Data Overview	21/12	PU
Annexon : ARCHER Trial Visual Acuity Results in Geographic Atrophy	21/12	PU
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock	21/12	GL
Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint	21/12	GL
Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway	21/12	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Annexon, Inc.

Equities

ANNX

US03589W1027

Press Releases

Filters